A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy (OAK)

NCT02008227 PHASE3 COMPLETED Results posted

This global, multicenter, open-label, randomized, controlled study evaluated the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 \[anti-PD-L1\] antibody)compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure with platinum-containing chemotherapy. Participants were randomized 1:1 to receive either docetaxel or atezolizumab. Treatment may continue as long as participants experienced clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.

Details

Lead sponsor	Hoffmann-La Roche
Phase	PHASE3
Status	COMPLETED
Enrolment	1225
Start date	Tue Mar 11 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jan 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Non-Squamous Non-Small Cell Lung Cancer

Interventions

• Atezolizumab
• Docetaxel

Countries

Italy, Panama, Finland, Japan, Taiwan, Poland, South Korea, Guatemala, New Zealand, Netherlands, Russia, Sweden, Thailand, Portugal, United States, France, Greece, Serbia, Austria, Chile, Hungary, Norway, Argentina, Canada, Brazil, Spain, Ukraine, United Kingdom, Germany, Switzerland